Twitxy Saved

EUMatrix.eu

@EumatrixEu

New EU-focused research platform which combines data-driven forecasts with experts' insights. Headed by @dorufrantescu, former CEO of VoteWatch Europe.
Belgium eumatrix.eu Joined October 2022
296 Following 529 Followers 424 Posts

Latest posts 5

EUMatrix.eu @EumatrixEu
🏛️ On 19 January, at the European Commission HaDEA Showcase, what was at stake was aligning EU funding to bolster competitiveness and preparedness—balancing technological autonomy versus global interdependence and harmonised rules versus rapid cross‑border deployment; #eupublicaffairs #europeanparliament #eupolicy #europeancommission #EUcouncil

Commission DGs and speakers split: autonomy-first voices (DG CONNECT led by Roberto Viola, DG HERA and DG RTD) pushed public‑private scale‑up of AI, supercomputing, space and dual‑use innovation, while DG GROW, EU4Health representatives and project leads urged strategic openness, permitting harmonisation and modular, replicable deployments to close the innovation-to-market gap.

Can the Commission secure strategic autonomy in health, digital and space without fragmenting the Single Market or deterring essential international partners?

Full analysis in comments ↓
EUMatrix.eu @EumatrixEu
🏛️ on 19 January in the European Parliament the Critical Medicines Act was debated: at stake was reducing dependence on China/India and scaling EU production while balancing centralised solidarity/procurement powers against subsidiarity and added environmental and regulatory costs (EU production vs global dependency; centralisation vs national sovereignty; environmental standards vs industrial competitiveness).

EPP pushed reshoring and procurement rules favouring EU manufacturers; S&D backed coordination and technical fixes but warned rigid procurement could harm smaller markets; Renew and Greens/EFA stressed green‑compatible industrial policy and joint procurement; ECR and PfE flagged overreach and regulatory burden; The Left pressed for patient‑centred access and to curb market concentration. #eupublicaffairs #europeanparliament #eupolicy #europeancommission #EUcouncil

Can the EU secure medicines and industrial capacity without centralising powers that undercut national health autonomy or exclude smaller producers?

Full analysis in comments ↓
EUMatrix.eu @EumatrixEu
🏛️ On 15 January in the European Parliament MEPs weighed whether rapid EU cross‑border energy and industrial scale‑up (PCI/PMI, hydrogen corridors, Battery Booster, Automotive Omnibus) should be prioritised over environmental sustainability, geopolitical risk management, consumer affordability and SME access — and whether speeding biotech authorisations can be reconciled with safety and public trust.

EPP pressed strategic partnerships, faster permitting and consumer campaigns; S&D pushed delivery to under‑connected regions and demand‑side support; Renew and Greens/EFA demanded strict hydrogen sustainability and stronger battery funding; ECR and PfE warned against over‑centralisation and regulatory burden; The Left focused on social safeguards, second‑hand EV markets and battery reuse #eupublicaffairs #europeanparliament #eupolicy #europeancommission #EUcouncil

Can the Parliament forge rules that accelerate infrastructure and industry without sacrificing sustainability, geopolitical resilience and equitable market access?

Full analysis in comments ↓
EUMatrix.eu @EumatrixEu
🏛️ On 15 December in the European Parliament a plenary debate focused on securing patient access to medicines amid geopolitical shocks — trading off strategic autonomy and supply‑chain resilience against industrial competitiveness, market‑driven innovation and open trade (US tariffs; China/India API dominance; war in Ukraine) #eupublicaffairs #europeanparliament #eupolicy #europeancommission #EUcouncil

EPP pushed a “buy European” industrial push and the Critical Medicines Act; S&D defended EU price negotiation and pan‑EU equality; Renew framed supply as a security issue and pressed EU procurement and clinical‑trial competitiveness; Greens/Left urged public production while ECR/PfE warned against overregulation and red tape.

Can the CMA and the pharmaceutical package reconcile near‑term resilience with long‑term competitiveness and equal access across Member States?

Full analysis in comments ↓